Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24174683 | 0.77 | HTT (0.34) | HTTPTK2 | |
| SCHEMBL20674123 | 0.76 | HTT (0.47) | HTTPTK2MAPTSLC2A1 | |
| SCHEMBL24553744 | 0.73 | HTT (0.44) | HTTPTK2MAPTSLC2A1 | |
| SCHEMBL21958684 | 0.73 | HTT (0.44) | HTTPTK2MAPTSLC2A1 | |
| SCHEMBL22693062 | 0.70 | HTT (0.41) | HTTPTK2MAPTSLC2A1 | |
| SCHEMBL16478438 | 0.70 | ADORA2A (0.36) | ADORA2AADORA1 | |
| SCHEMBL14985864 | 0.70 | HTT (0.42) | HTTXDHADORA2AADORA1 | |
| SCHEMBL19964519 | 0.68 | HTT (0.52) | HTTPTK2MAPTSLC2A1 | |
| SCHEMBL22693056 | 0.67 | MAPT (0.37) | HTTPTK2MAPTADORA1 | |
| SCHEMBL18742150 | 0.64 | TNKS2 (0.50) | HTTADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | HTT 4062/4885PTK2 2557/4885MAPT 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.